World-renowned cancer immunotherapy specialist Targovax recently added a pair of highly experienced executives -- Anne-Kirsti Aksnes and Tina Madsen -- to leadership roles in the company.
Aksnes assumes the role of vice president of clinical development, while Madsen will serve as vice president of quality assurance. Both have 20 years or more experience in the industry.
Aksnes’ experience is in clinical research and development in the pharma and biotech industry and in clinical physiology. She was previously the vice president of clinical research at Algeta ASA (now Bayer AS).
Madsen has experience in commercial manufacturing and research and development in the pharma and biotech industries, related to quality assurance, process development and formulation. Before joining Targovax, she was the director of product quality assurance for Algeta ASA.
“I am pleased to welcome Anne-Kirsti and Tina to our team,” Targovax CEO Gunnar Gårdemyr said. “We look forward to the insight and wealth of experience that they bring to Targovax.”
Targovax, established in 2010, is entering a new development phase. By expanding the professional and experienced management team with these two new senior executives, company officials said it is in a strong position to plan and execute its proof of concept studies.